https://renovorx.com/renovorx-baybio-entrepreneur-investor-roundtables/2013-02-12T23:00:00+00:00https://renovorx.com/renovorxs-board-directors-member-larry-marton-speaks-personalized-medicine/2013-08-20T22:08:54+00:00https://renovorx.com/renovorx-announces-new-board-directors-members/2013-01-25T22:53:37+00:00https://renovorx.com/renovorx-featured-start/2013-02-27T23:01:17+00:00https://renovorx.com/iso-13485-certification/2015-03-02T18:58:50+00:00https://renovorx.com/first-in-human-use-renovocath-catheter/2015-05-07T15:00:00+00:00https://renovorx.com/first-patient-enrolled-renovocath-clinical-study/2015-06-03T15:45:08+00:00https://renovorx.com/renovorx-receives-ce-mark-for-renovocath/2015-10-20T16:00:17+00:00https://renovorx.com/renovorx-joins-stanford-startx-med-program/2015-11-19T16:45:49+00:00https://renovorx.com/analysis-data-localized-delivery-chemotherapy-pancreatic-cancer/2016-05-23T20:06:52+00:00https://renovorx.com/renovorx-begins-post-market-registry-study/2016-02-01T21:14:40+00:00https://renovorx.com/renovorx-announces-u-s-patent-trademark-office-issuance-two-patents/2016-10-13T21:18:58+00:00https://renovorx.com/renovorx-announces-fda-clearance-expanded-labeling/2017-03-30T23:30:41+00:00https://renovorx.com/researchers-report-survival-benefits-use-renovocath-patients-locally-advanced-pancreatic-tumors/2017-04-19T16:42:44+00:00https://renovorx.com/intra-arterial-targeted-delivery-gemcitabine-treatment-patients-loco-regional-pancreatic-tumors/2017-04-02T18:59:41+00:00https://renovorx.com/presentation-tumor-cases-treated-embolotherapy/2016-11-26T01:15:14+00:00https://renovorx.com/renovorx-announces-10-million-financing-innovative-treatment-advanced-pancreatic-cancer/2018-05-23T17:17:16+00:00https://renovorx.com/all-about-cancer-with-dr-ripal-gandhi-dr-raj-narayanan-dr-horacio-asbun/2018-11-28T23:48:57+00:00https://renovorx.com/contemporary-management-of-pancreatic-cancer/2019-10-01T23:56:55+00:00https://renovorx.com/renovorx-announces-issuance-of-fifth-u-s-patent/2020-01-08T20:25:16+00:00https://renovorx.com/parexel-biotech-and-renovorx-reach-key-milestone-in-pancreatic-cancer-clinical-trial-for-locally-advanced-pancreatic-cancer/2020-01-13T18:32:35+00:00https://renovorx.com/renovorx-announces-orphan-drug-designation-granted-for-treating-bile-duct-cancer/2020-06-02T20:54:22+00:00https://renovorx.com/renovorx-announces-issuance-of-sixth-u-s-patent/2020-06-09T01:00:43+00:00https://renovorx.com/renovorx-named-2020-drug-delivery-technology-winner-in-the-fierce-innovation-awards-for-life-sciences/2020-09-15T17:16:41+00:00https://renovorx.com/renovorx-continues-with-strong-momentum-and-reaches-milestone-of-100th-patient-enrolled-in-its-phase-iii-tiger-pac-clinical-trial/2020-12-02T16:36:35+00:00https://renovorx.com/renovorx-announces-studies-that-further-advance-the-science-of-pancreatic-cancer-treatment-presented-at-the-2021-asco-gastrointestinal-cancers-symposium/2021-01-20T01:58:26+00:00https://renovorx.com/renovorx-announces-issuance-of-seventh-u-s-patent/2021-07-08T08:00:19+00:00https://renovorx.com/renovorx-announces-new-board-of-directors-members/2013-01-25T20:19:22+00:00https://renovorx.com/renovorx-at-baybio-entrepreneur-and-investor-roundtables/2013-02-12T20:22:55+00:00https://renovorx.com/renovorx-featured-by-start-up/2013-02-27T20:23:27+00:00https://renovorx.com/renovorx-named-tie50-winner-2013/2013-05-20T20:24:11+00:00https://renovorx.com/renovorxs-board-of-directors-member-larry-marton-speaks-on-personalized-medicine/2013-08-20T20:24:38+00:00https://renovorx.com/renovorx-board-names-shaun-r-bagai-as-ceo/2014-10-27T20:25:02+00:00https://renovorx.com/renovorx-patent-issued/2014-10-28T20:25:24+00:00https://renovorx.com/renovocath-rc120-receives-fda-510k-clearance/2014-10-30T20:25:45+00:00https://renovorx.com/renovorx-achieves-iso-13485-certification/2015-03-02T20:26:27+00:00https://renovorx.com/first-in-human-use-of-renovocath-catheter-2/2015-05-07T20:37:21+00:00https://renovorx.com/first-patient-enrolled-in-study-using-the-renovocath/2015-06-03T20:39:10+00:00https://renovorx.com/renovorx-receives-ce-mark/2015-10-20T20:40:06+00:00https://renovorx.com/renovorx-joins-stanford-backed-startx-med-program/2015-11-19T20:41:08+00:00https://renovorx.com/renovorx-begins-post-market-study/2016-02-01T20:41:38+00:00https://renovorx.com/interim-analysis-of-data-on-localized-delivery-of-chemotherapy-for-pancreatic-cancer/2016-05-23T20:42:23+00:00https://renovorx.com/renovorx-announces-the-u-s-patent-and-trademark-office-issuance-of-two-patents/2016-10-13T20:42:51+00:00https://renovorx.com/presentation-of-tumor-cases-treated-with-embolotherapy/2016-11-25T20:43:33+00:00https://renovorx.com/renovorx-announces-fda-clearance-for-expanded-labeling/2017-03-30T20:44:10+00:00https://renovorx.com/presentation-of-data-on-intra-arterial-targeted-delivery-of-gemcitabine-in-treatment-of-loco-regional-pancreatic-tumors/2017-04-02T20:44:47+00:00https://renovorx.com/researchers-report-survival-benefits-with-use-of-renovocath-in-patients-with-locally-advanced-pancreatic-tumors/2017-04-19T20:47:18+00:00https://renovorx.com/renovorx-announces-10-million-financing-for-innovative-treatment-for-advanced-pancreatic-cancer/2018-05-23T20:48:06+00:00https://renovorx.com/all-about-cancer-with-doctors/2018-11-28T20:48:44+00:00https://renovorx.com/new-cancer-procedure-gifts-bay-area-couple-3-more-years/2019-05-02T20:50:04+00:00https://renovorx.com/woman-receiving-experimental-treatments-for-pancreatic-cancer-at-upmc/2019-07-15T20:50:49+00:00https://renovorx.com/contemporary-management-pancreatic-cancer/2019-10-01T20:51:26+00:00https://renovorx.com/renovorx-announces-issuance-of-fifth-us-patent/2020-01-08T20:52:06+00:00https://renovorx.com/parexel-biotech-and-renovorx-reach-key-milestone/2020-01-13T20:53:00+00:00https://renovorx.com/renovorx-announces-orphan-drug-designation-granted-for-treatment-of-bile-duct-cancer/2020-06-02T20:53:41+00:00https://renovorx.com/renovorx-announces-sixth-u-s-patent/2020-06-09T20:54:35+00:00https://renovorx.com/renovorx-named-2020-winner-in-the-fierce-innovation-awards-for-life-sciences/2020-09-15T20:55:05+00:00https://renovorx.com/new-pancreatic-cancer-treatment-may-add-years/2020-09-29T20:55:35+00:00https://renovorx.com/renovorx-continues-with-strong-momentum/2020-12-02T20:56:36+00:00https://renovorx.com/renovorx-announces-studies-that-further-advance-the-science-of-pancreatic-cancer/2021-01-20T20:57:16+00:00https://renovorx.com/pancreatic-cancer-patient-receives-new-treatment/2021-04-05T20:58:03+00:00https://renovorx.com/doctors-test-groundbreaking-treatment-for-pancreatic-cancer/2021-06-02T20:58:44+00:00https://renovorx.com/renovorx-announces-seventh-u-s-patent/2021-07-08T20:59:33+00:00https://renovorx.com/renovorx-announces-pricing-of-initial-public-offering/2021-08-25T03:37:32+00:00https://renovorx.com/renovorx-announces-pricing-of-ipo/2021-08-26T04:07:40+00:00https://renovorx.com/renovorx-receives-new-510k-clearance-for-its-renovocath-delivery-system-designed-for-targeted-treatment-of-solid-tumors/2021-09-07T15:19:30+00:00https://renovorx.com/renovorx-receives-new-510k-clearance-for-its-renovocath-delivery-system/2021-09-07T15:20:08+00:00https://renovorx.com/presentation-during-new-advances-in-management-of-pancreatic-cancer-course-highlights-intra-arterial-chemotherapy-as-a-potential-innovative-treatment-for-pancreatic-cancer/2021-11-09T18:53:38+00:00https://renovorx.com/presentation-during-new-advances-in-the-management-of-pancreatic-cancer-course-highlights-intra-arterial-chemotherapy-as-a-potential-innovative-treatment-for-pancreatic-cancer/2021-11-09T18:53:30+00:00https://renovorx.com/renovorx-announces-presentation-of-final-data-from-rr2-observational-registry-study-2021-pancreas-club-annual-meeting/2021-11-11T10:00:24+00:00https://renovorx.com/renovorx-announces-3rd-quarter-2021-financial-results/2021-11-15T08:15:07+00:00https://renovorx.com/renovorx-announces-third-quarter-2021-financial-results/2021-11-15T08:15:09+00:00https://renovorx.com/renovorx-to-present-at-the-hc-wainwright-bioconnect-virtual-conference/2022-01-06T12:00:00+00:00https://renovorx.com/renovorx-to-present-at-hc-wainwright-bioconnect-virtual-conference/2022-01-06T12:00:39+00:00https://renovorx.com/renovorx-announces-presentation-at-the-2022-spectrum-conference-highlighting-innovative-renovotamp-therapy-for-targeted-treatment-of-cancer/2022-01-19T12:00:47+00:00https://renovorx.com/renovorx-announces-presentation-at-the-2022-spectrum-conference-highlighting-its-innovative-renovotamp-therapy-for-targeted-treatment-of-cancer/2022-01-19T12:00:52+00:00https://renovorx.com/renovorx-to-host-delivering-therapy-where-it-matters-fireside-chat-with-ceo-shaun-bagai/2022-02-03T13:00:41+00:00https://renovorx.com/renovorx-to-host-delivering-therapy-where-it-matters-fireside-chat-with-ceo-shaun-bagai-2/2022-02-03T13:00:10+00:00https://renovorx.com/shaun-bagai-discusses-the-renovorx-revolution-2/2022-03-09T19:35:37+00:00https://renovorx.com/renovorx-to-participate-in-march-2022-investor-conferences/2022-03-11T12:30:01+00:00https://renovorx.com/renovorx-to-participate-march-2022-investor-conferences/2022-03-11T12:30:04+00:00https://renovorx.com/trans-arterial-treatment-option-in-pancreas-cancer-presented-at-2022-spectrum-conference-january-14-16-2022/2022-01-16T20:31:50+00:00https://renovorx.com/renovorx-announces-presentation-of-final-data-from-rr2-observational-registry-study-at-2021-pancreas-club-annual-meeting-presented-at-pancreas-club-2021-november-11-12-2021/2021-11-12T20:35:27+00:00https://renovorx.com/potential-future-innovative-strategy-for-pancreatic-cancer-intra-arterial-chemotherapy-presented-at-miami-cancer-institutes-new-advances-in-the-management-of-pancreatic-cancer-november-9/2021-11-09T20:45:26+00:00https://renovorx.com/validating-and-optimizing-trans-arterial-micro-perfusion-using-a-novel-double-balloon-catheter-in-a-pig-model-for-local-delivery-of-chemotherapy-to-solid-tumors-presented-at-sir-2021-annual-scientif/2021-03-26T20:46:44+00:00https://renovorx.com/sepsis-and-pancreatic-cancer-biliary-stents-a-significant-risk-factor-in-patients-undergoing-chemotherapy-presented-at-2021-asco-gastrointestinal-cancers-symposium-january-15-17-2021/2021-01-17T20:52:11+00:00https://renovorx.com/resection-rate-of-locally-advanced-pancreatic-cancer-in-gemcitabine-plus-nab-paclitaxel-versus-folfirinox-presented-at-2021-asco-gastrointestinal-cancers-symposium-january-15-17-2021/2021-01-17T20:53:40+00:00https://renovorx.com/trans-arterial-chemotherapy-for-treatment-of-locally-advanced-pancreatic-cancer-treatment-factors-impacting-survival-presented-at-sir-2020-virtual-june-13-14-2020/2020-06-14T20:55:11+00:00https://renovorx.com/targeted-intra-arterial-gemcitabine-impact-on-survival-in-patients-with-locally-advanced-pancreatic-cancer-a-new-treatment-paradigm-presented-at-the-world-congress-on-pancreatic-cancer-l/2019-10-23T20:57:05+00:00https://renovorx.com/management-of-advanced-stage-hepatocellular-carcinoma-with-extensive-portal-vein-tumor-thrombus-using-an-adjustable-dual-balloon-occlusion-technique-published-in-journal-of-vascular-and-intervention/2019-07-01T21:04:39+00:00https://renovorx.com/localized-intra-arterial-gemcitabine-impact-on-survival-in-patients-with-lapc-a-new-treatment-paradigm-presented-at-pancreas-club-annual-meeting-may-18-2019/2019-05-18T21:06:15+00:00https://renovorx.com/new-experience-with-transarterial-micro-perfusion-tamp-presented-at-gest-2019-may-11-2019/2019-05-11T21:07:45+00:00https://renovorx.com/safety-study-of-targeted-and-localized-intra-arterial-delivery-of-gemcitabine-in-patients-with-locally-advanced-pancreatic-adenocarcinoma-journal-of-pancreatic-cancer-august-2017/2017-08-28T21:10:38+00:00https://renovorx.com/intra-arterial-targeted-delivery-of-gemcitabine-in-treatment-of-patients-with-loco-regional-pancreatic-tumors-presented-at-ahpba-annual-meeting-april-2-2017/2017-04-02T21:11:41+00:00https://renovorx.com/pancreatic-cancer-chemoembolization-using-a-double-balloon-catheter-presented-at-aim-symposium-november-14-2016/2016-11-14T21:17:56+00:00https://renovorx.com/intra-arterial-targeted-delivery-of-gemcitabine-in-treatment-of-patients-with-loco-regional-pancreatic-tumors-poster-presented-to-50th-annual-pancreas-club-meeting-may-20-21-2016/2016-05-21T21:19:13+00:00https://renovorx.com/pancreas-club-abstract-is-intra-arterial-with-targeted-delivery-of-gemcitabine-safe-in-treatment-of-patients-with-loco-regional-pancreatic-tumors-may-20-21-2016/2016-05-21T21:21:06+00:00https://renovorx.com/ihpba-2016-abstract-intra-arterial-and-tumor-targeted-infusion-of-gemcitabine-in-patients-with-unresectable-pancreatic-cancer-april-20-23-2016/2016-04-23T21:23:42+00:00https://renovorx.com/renovorx-reports-full-year-2021-financial-results/2022-03-30T13:30:47+00:00https://renovorx.com/renovorx-reports-full-year-21-financial-results/2022-03-30T13:30:57+00:00https://renovorx.com/renovorx-enrolls-1st-pancreatic-cancer-patient-at-columbia-universitys-new-york-presbyterian-hospital-irving-medical-center-in-ongoing-tiger-pac-phase-3-clinical-trial/2022-02-22T12:00:06+00:00https://renovorx.com/renovorx-enrolls-first-pancreatic-cancer-patient-at-columbia-universitys-new-york-presbyterian-hospital-irving-medical-center-in-ongoing-tiger-pac-phase-3-clinical-trial/2022-02-22T12:00:04+00:00https://renovorx.com/shaun-bagai-discusses-the-renovorx-revolution/2022-03-09T19:24:35+00:00https://renovorx.com/late-stage-clinical-biopharmaceutical-company-with-novel-therapy-platform-to-treat-locally-advanced-solid-tumors-presented-at-h-c-wainwright-bioconnect-conference-january-2022/2022-01-22T18:16:34+00:00https://renovorx.com/delivering-therapy-where-it-matters-fireside-chat-with-ceo-shaun-bagai-webinar-february-2022/2022-02-01T18:19:23+00:00https://renovorx.com/late-stage-clinical-biopharmaceutical-company-with-novel-therapy-platform-to-treat-locally-advanced-solid-tumors-presented-at-roth-capital-partners-34th-annual-conference-march-2022/2022-03-22T18:20:30+00:00https://renovorx.com/late-stage-clinical-biopharmaceutical-company-with-novel-therapy-platform-to-treat-locally-advanced-solid-tumors-presented-at-maxim-virtual-growth-conference-march-2022/2022-04-07T22:03:30+00:00https://renovorx.com/late-stage-clinical-biopharmaceutical-company-with-novel-therapy-platform-to-treat-locally-advanced-solid-tumors-presented-at-roth-capital-partners-34th-annual-conference-march-2022-2/2022-04-19T00:24:03+00:00https://renovorx.com/renovorx-raises-funds-awareness-to-fight-worlds-toughest-cancer/2022-04-19T00:30:55+00:00https://renovorx.com/renovorx-raises-funds-and-awareness-to-fight-worlds-toughest-cancer/2022-04-19T00:30:58+00:00https://renovorx.com/renovorx-reports-first-quarter-2022-financial-results/2022-05-16T12:30:02+00:00https://renovorx.com/renovorx-reports-1st-quarter-2022-financial-results/2022-05-16T12:30:05+00:00https://renovorx.com/renovorx-to-participate-in-upcoming-h-c-wainwright-global-investment-conference-in-may-2022/2022-05-18T12:30:46+00:00https://renovorx.com/renovorx-to-participate-in-upcoming-hc-wainwright-global-investment-conference-in-may-2022/2022-05-18T12:30:59+00:00https://renovorx.com/renovorx-to-present-preclinical-research-data-demonstrating-its-innovative-therapy-platforms-potential-utility-for-the-treatment-of-bile-duct-cancer/2022-05-19T12:30:25+00:00https://renovorx.com/renovorx-announces-preclinical-research-data-demonstrating-innovative-therapy-platforms-potential-utility-for-treatment-of-bile-duct-cancer/2022-05-19T12:30:16+00:00https://renovorx.com/localized-delivery-of-chemotherapy-through-the-bile-duct-using-a-double-balloon-catheter-in-a-porcine-model-presented-at-global-embolization-oncologysymposium-technologies-gest-2022-may-19-2022/2022-05-18T12:30:44+00:00https://renovorx.com/renovorx-to-participate-in-the-university-of-cambridges-academy-of-therapeutic-sciences-gateway-to-translation-seminar-series-on-june-8-2022/2022-06-02T12:30:24+00:00https://renovorx.com/renovorx-to-participate-in-university-of-cambridges-academy-of-therapeutic-sciences-gateway-to-translation-seminar-series-on-june-8-2022/2022-06-02T12:30:07+00:00https://renovorx.com/renovorx-and-tiger-pac-leadership-to-host-renovotamp-webinar-on-june-21-2022/2022-06-09T12:30:39+00:00https://renovorx.com/renovorx-and-tiger-pac-leadership-to-host-renovotamp-webinar-on-june-21-22/2022-06-09T12:30:41+00:00https://renovorx.com/localized-intra-arterial-drug-delivery-for-treatment-of-solid-tumors-presented-at-university-of-cambridge-academy-of-therapeutic-sciences-gateway-to-translation-seminar-series-june-8-2022/2022-06-09T00:47:15+00:00https://renovorx.com/facing-todays-challenges-in-pancreatic-cancer-treatment-webinar-june-2022/2022-06-27T18:01:45+00:00https://renovorx.com/renovorx-appoints-james-ahlers-as-chief-financial-officer-and-expands-finance-team-with-addition-of-ronald-kocak-cpa-as-vice-president-and-controller/2022-07-19T12:30:28+00:00https://renovorx.com/renovorx-appoints-james-ahlers-as-chief-financial-officer-and-expands-finance-team-with-addition-of-ronald-b-kocak-cpa-as-vice-president-and-controller/2022-07-19T12:30:23+00:00https://renovorx.com/renovorx-launches-the-renovorx-story-video-series-spotlighting-the-renovorx-journey-leadership-and-innovative-treatment-platform-targeting-difficult-to-treat-cancers/2022-07-11T12:00:47+00:00https://renovorx.com/renovorx-launches-the-renovorx-story-video-series-spotlighting-the-renovorx-journey-its-leadership-and-innovative-treatment-platform-targeting-difficult-to-treat-cancers/2022-07-13T12:00:49+00:00https://renovorx.com/the-renovorx-story-video-series-interview-with-ceo-shaun-bagai-july-2022/2022-07-13T12:00:17+00:00https://renovorx.com/the-renovorx-story-video-2-targeted-cancer-treatment-utilizing-renovorxs-novel-therapy-platform-july-27-2022/2022-07-27T19:04:09+00:00https://renovorx.com/the-renovorx-story-video-3-fighting-difficult-to-treat-cancers-via-localized-treatment-august-10-2022/2022-08-10T15:00:56+00:00https://renovorx.com/renovorx-reports-second-quarter-2022-financial-results/2022-08-15T12:00:40+00:00https://renovorx.com/renovorx-reports-2nd-quarter-2022-financial-results/2022-08-15T12:00:12+00:00https://renovorx.com/renovorx-appoints-angela-gill-nelms-as-chief-operating-officer/2022-09-19T12:30:35+00:00https://renovorx.com/trans-arterial-micro-perfusion-therapy-for-pancreatic-cancer-presented-at-symposium-on-clinical-interventional-oncology-september-23-25-2022/2022-09-27T20:10:50+00:00https://renovorx.com/renovorx-announces-presentation-at-symposium-on-clinical-interventional-oncology-cio-highlighting-its-innovative-therapy-platform-for-targeted-treatment-of-pancreatic-cancer/2022-09-28T12:30:20+00:00https://renovorx.com/renovorx-to-participate-in-upcoming-october-2022-investor-conferences/2022-10-04T12:45:44+00:00https://renovorx.com/treatment-of-hepatic-tumors-with-inaccessible-vasculature-using-an-adjustable-length-dual-occlusion-balloon-catheter-system-journal-of-vascular-interventional-radiology-september-2018/2018-09-01T21:00:29+00:00https://renovorx.com/renovorx-reports-third-quarter-2022-financial-results/2022-11-14T18:00:47+00:00https://renovorx.com/renovorx-announces-presentations-at-the-advanced-interventional-management-symposium-aimsymposium-highlighting-its-innovative-renovotamp-therapy-platform-for-targeted-treatment-of-cancers/2022-11-17T22:23:41+00:00https://renovorx.com/renovorx-announces-acceptance-of-four-clinical-data-abstracts-at-the-2023-asco-gastrointestinal-cancers-asco-gi-symposium/2022-12-15T12:30:43+00:00https://renovorx.com/renovorx-strengthens-intellectual-property-ip-portfolio-with-eighth-us-patent/2023-01-05T12:30:45+00:00https://renovorx.com/renovorx-announces-initial-results-in-pharmacokinetic-pk-substudy-data-on-renovogem-supports-potential-for-renovotamp-therapy-platform-to-increase-local-gemcitabine-chemotherapy-de/2023-01-18T12:30:13+00:00https://renovorx.com/intra-arterial-gemcitabine-vs-iv-gemcitabine-pk-substudy-in-patients-with-locally-advanced-pancreatic-cancer-presented-at-the-2023-the-2023-asco-gastrointestinal-asco-gi-cancers-symposium2/2023-01-21T01:38:01+00:00https://renovorx.com/incidence-and-clinical-characteristics-of-patients-with-lapc-and-mesenteric-vein-thrombosis-and-current-treatment-paradigm-presented-at-the-2023-the-2023-asco-gastrointestinal-asco-gi-cancers-sympos/2023-01-21T00:40:15+00:00https://renovorx.com/toxicity-and-efficacy-of-stereotactic-body-radiation-therapy-vs-intensity-modulated-radiation-therapy-for-the-treatment-of-locally-advanced-pancreatic-cancer-in-a-phase-3-trial-presented-at-the-2023/2023-01-21T00:39:44+00:00https://renovorx.com/targeted-intra-arterial-gemcitabine-vs-continuation-of-iv-gemcitabine-plus-nab-paclitaxel-following-induction-with-sequential-iv-gemcitabine-plus-nab-paclitaxel-and-radiotherapy-for-unresectable-loca/2023-01-21T00:38:57+00:00https://renovorx.com/intra-arterial-versus-intravenous-gemcitabine-administration-pk-substudy-within-the-phase-iii-tiger-pac-clinical-trial-in-locally-advanced-pancreatic-cancer-presented-on-oncologytube-2023/2023-02-13T18:08:22+00:00https://renovorx.com/renovorx-phase-iii-open-label-tiger-pac-interim-analysis-shows-promising-data-that-support-continued-clinical-investigation-of-renovogemtm-as-a-treatment-option-for-locally-advanced-pancreatic-cancer/2023-03-08T12:30:08+00:00https://renovorx.com/renovorx-announces-positive-new-data-from-phase-iii-clinical-trial-interim-analysis-60-survival-benefit-and-fewer-side-effects-than-systemic-chemotherapy/2023-03-30T12:30:05+00:00https://renovorx.com/renovorx-appoints-leesa-gentry-as-senior-vice-president-of-clinical-operations/2023-04-11T12:30:10+00:00https://renovorx.com/renovorx-presenting-phase-iii-clinical-trial-interim-analysis-data-of-the-tiger-pac-study-at-american-association-for-cancer-research-annual-meeting-underway-in-orlando-florida/2023-04-14T12:30:04+00:00https://renovorx.com/renovorx-appoints-former-chief-medical-officer-of-schering-plough-robert-j-spiegel-md-facp-to-board-of-directors/2023-04-27T12:30:01+00:00https://renovorx.com/renovorx-sponsors-pancreatic-cancer-action-networks-purplestride-event/2023-05-02T01:01:47+00:00https://renovorx.com/renovorx-announces-late-breaking-oral-presentation-at-2023-esmo-world-congress-on-gastrointestinal-cancer/2023-05-26T02:25:36+00:00https://renovorx.com/renovorx-initiates-patient-enrollment-at-university-of-texas-southwestern-medical-center-for-pivotal-phase-iii-tiger-pac-clinical-trial/2023-06-01T12:45:21+00:00https://renovorx.com/renovorx-appoints-margaret-a-tempero-m-d-to-scientific-advisory-board/2023-06-19T20:50:54+00:00https://renovorx.com/the-phase-3-study-targeted-intra-arterial-gemcitabine-vs-continuation-of-iv-gemcitabine-plus-nab-paclitaxel-following-induction-with-sequential-iv-gemcitabine-plus-nab-paclitaxel-and-radiotherapy-fo/2023-06-27T21:15:23+00:00https://renovorx.com/renovorx-announces-new-positive-interim-phase-iii-data-demonstrating-renovogem-delays-cancer-progression-by-eight-months-in-locally-advanced-pancreatic-cancer/2023-06-29T12:15:35+00:00https://renovorx.com/trans-pulmonary-artery-selective-chemotherapy-delivery-to-lung-using-a-double-balloon-occlusion-catheter-feasibility-study-in-swine-presented-at-sir-2019-annual-meeting-march-23-28-2019/2019-03-13T23:55:13+00:00https://renovorx.com/renovorx-and-imugene-announce-collaboration-to-deliver-oncolytic-virus-therapy-using-proprietary-trans-arterial-micro-perfusion-tamp-platform/2023-07-20T12:00:33+00:00https://renovorx.com/intra-arterial-gemcitabine-extends-pfs-in-locally-advanced-pancreatic-cancer/2023-07-05T19:10:07+00:00https://renovorx.com/renovorx-presents-positive-interim-phase-iii-data-in-pancreatic-cancer/2023-07-29T19:15:50+00:00https://renovorx.com/intra-arterial-gemcitabine-improves-os-in-locally-advanced-pancreatic-cancer/2023-06-29T19:22:12+00:00https://renovorx.com/renovorxs-tamp-platform-will-deliver-imugenes-cf33-oncolytic-virotherapy-in-companies-research-collaboration/2023-07-20T19:32:09+00:00https://renovorx.com/survival-benefit-shown-with-ia-gemcitabine-in-patients-with-locally-advanced-pancreatic-cancer/2023-07-10T19:33:08+00:00https://renovorx.com/renovorx-imugene-partner-to-deliver-oncolytic-virus-therapy/2023-07-24T16:56:58+00:00https://renovorx.com/intra-arterial-gemcitabine-showed-promise-for-locally-advanced-pancreatic-cancer/2023-08-15T17:16:25+00:00https://renovorx.com/intra-arterial-approach-to-locally-advanced-pancreatic-cancer/2023-08-30T15:43:54+00:00https://renovorx.com/renovorx-expands-scientific-advisory-board-with-appointment-of-michel-ducreux/2023-11-28T17:26:19+00:00https://renovorx.com/renovorx-files-new-international-patent-for-novel-targeted-combination-drug-delivery-oncology-therapy-platform/2023-12-14T12:30:11+00:00https://renovorx.com/renovorx-announces-clinical-data-abstract-at-the-2024-society-of-interventional-radiology-annual-scientific-meeting/2023-12-19T18:07:45+00:00https://renovorx.com/renovorx-engages-oklahoma-university-ou-health-as-first-clinical-site-in-preparation-for-the-pivotal-phase-iii-cougar-clinical-trial-in-bile-duct-cancer/2023-12-21T23:24:49+00:00https://renovorx.com/renovorx-highlights-key-leadership-promotions/2024-03-08T23:19:38+00:00https://renovorx.com/renovorx-highlights-recent-presentation-of-clinical-data-abstract-at-the-2024-society-of-interventional-radiology-annual-scientific-meeting/2024-04-17T22:38:46+00:00https://renovorx.com/publication-of-results-of-pre-clinical-studies-support-efficacy-and-drug-delivery-mechanism-potential-of-renovorxs-tamp-therapy-platform-to-improve-targeted-cancer-drug-treatment-de/2024-05-21T23:28:02+00:00https://renovorx.com/renovorx-appoints-ryan-witt-as-senior-vice-president-head-of-corporate-strategy-and-partnerships/2024-06-10T12:30:46+00:00https://renovorx.com/university-of-nebraska-medical-center-launches-patient-enrollment-for-renovorxs-pivotal-phase-iii-tiger-pac-clinical-trial/2024-06-27T19:38:30+00:00https://renovorx.com/trans-arterial-micro-perfusion-for-improved-drug-delivery/2024-06-19T16:21:12+00:00https://renovorx.com/renovorx-announces-acceptance-for-publication-in-the-international-peer-reviewed-journal-the-oncologist/2024-07-09T19:55:32+00:00https://renovorx.com/renovorx-announces-publication-of-positive-early-stage-clinical-data-in-international-peer-reviewed-journal-the-oncologist/2024-08-01T21:18:11+00:00https://renovorx.com/treatment-of-locally-advanced-pancreatic-cancer-using-localized-trans-arterial-micro-perfusion-of-gemcitabine-combined-analysis-of-rr1-and-rr2-published-in-the-oncologist-july-2024/2024-08-01T21:28:50+00:00https://renovorx.com/renovorx-announces-first-patient-enrolled-at-university-of-nebraska-medical-center-for-the-ongoing-pivotal-phase-iii-tiger-pac-clinical-trial/2024-08-14T19:34:40+00:00https://renovorx.com/double-balloon-catheter-mediated-transarterial-chemotherapy-delivery-in-a-swine-model-a-mechanism-recruiting-the-vasa-vasorum-for-localized-therapies-published-in-the-journal-of-vascular-and/2024-03-18T22:57:48+00:00https://renovorx.com/renovorx-announces-presentation-at-symposium-on-clinical-interventional-oncology-highlighting-tamptm-for-targeted-treatment-of-locally-advanced-pancreatic-cancer/2024-09-19T13:00:12+00:00https://renovorx.com/renovorx-increases-production-of-fda-cleared-renovocath-delivery-system-in-response-to-strong-demand-from-oncology-and-interventional-radiology-physicians/2024-09-25T22:46:18+00:00https://renovorx.com/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorxs-ongoing-pivotal-phase-iii-tiger-pac-clinical-trial/2024-11-20T22:44:28+00:00https://renovorx.com/interventional-approaches-for-locally-advanced-pancreatic-cancer/2024-11-20T22:52:45+00:00https://renovorx.com/renovorx-receives-first-purchase-orders-for-its-fda-cleared-renovocath-delivery-system/2026-10-05T20:51:07+00:00https://renovorx.com/renovorx-initiates-patient-enrollment-at-scri-oncology-partners-for-ongoing-pivotal-phase-iii-tiger-pac-clinical-trial-in-locally-advanced-pancreatic-cancer/2026-10-05T20:51:09+00:00https://renovorx.com/renovorx-continues-to-grow-intellectual-property-portfolio-for-its-novel-drug-delivery-therapy-platform/2026-10-05T20:51:09+00:00https://renovorx.com/renovorx-announces-acceptance-of-abstract-for-presentation-at-asco-gastrointestinal-cancers-symposium-2025/2026-10-05T20:51:09+00:00https://renovorx.com/intra-arterial-gemcitabine-vs-iv-gemcitabine-pharmacokinetic-sub-study-of-the-tiger-pac-phase-3-clinical-trial-presented-at-asco-gastrointestinal-cancers-symposium-january-20245/2025-01-30T21:02:16+00:00https://renovorx.com/renovorx-highlights-promising-pharmacokinetic-data-abstract-presented-at-asco-gi-2025/2026-10-05T20:51:09+00:00https://renovorx.com/mesenteric-venous-thrombosis-as-a-predictor-of-target-artery-thrombosis-and-trans-arterial-micro-perfusion-treatment-completion-among-patients-with-locally-advanced-pancreatic-cancer-presented-at-soci/2024-03-31T00:39:48+00:00https://renovorx.com/renovorx-highlights-promising-pre-clinical-data-abstract-tamp-therapy-platform-offers-potential-to-improve-localized-and-targeted-drug-delivery/2026-10-05T20:51:09+00:00https://renovorx.com/micro-ct-imaging-following-intra-arterial-delivery-of-a-radiopaque-silicone-polymer-using-a-double-balloon-occlusion-catheter-in-pigs-a-model-to-analyze-tissue-penetration-via-the-trans-arterial-micr/2025-02-13T22:36:40+00:00https://renovorx.com/renovorx-advances-commercialization-of-renovocath-with-several-new-purchase-orders-including-customer-reorders/2026-10-05T20:51:10+00:00https://renovorx.com/renovorx-announces-abstract-presentation-at-the-society-of-surgical-oncology-sso-2025/2026-10-05T20:51:10+00:00https://renovorx.com/renovorx-pre-clinical-results-supporting-tamp-as-a-targeted-locoregional-drug-delivery-platform-to-receive-award-at-sir-2025-annual-scientific-meeting/2026-10-05T20:51:10+00:00https://renovorx.com/renovorx-highlights-new-human-pharmacokinetic-data-abstract-at-sso-2025-annual-meeting/2026-10-05T20:51:10+00:00https://renovorx.com/pharmacodynamics-of-intra-arterial-vs-intravenous-gemcitabine-in-locally-advanced-pancreatic-cancer-results-of-a-phase-iii-randomized-clinical-trial-pharmacodynamics-of-intra-arterial-vs-intravenous/2025-03-28T17:20:02+00:00https://renovorx.com/johns-hopkins-medicine-initiates-patient-enrollment-for-renovorxs-ongoing-phase-iii-tiger-pac-clinical-trial/2026-10-05T20:51:12+00:00https://renovorx.com/u-s-patent-office-issues-new-patent-to-renovorx-for-novel-trans-arterial-micro-profusion-tamp-therapy-platform/2026-10-05T20:51:12+00:00https://renovorx.com/ahpba-2026-annual-meeting-miami-fl-march-19-22-2026/2020-03-19T07:00:14+00:00https://renovorx.com/renovorxs-panther-post-marketing-registry-study-progresses-with-first-clinical-procedure-and-addition-of-two-participating-clinical-sites/2026-10-05T20:51:12+00:00https://renovorx.com/renovorx-expands-u-s-commercialization-efforts-for-the-renovocath-device-with-growing-customer-demand-and-key-leadership-hire/2026-10-05T20:51:12+00:00https://renovorx.com/renovorx-launches-multi-center-post-marketing-registry-study-to-evaluate-cancer-treatment-delivered-by-renovocath-device-to-solid-tumors/2026-10-05T20:51:13+00:00https://renovorx.com/renovorx-expands-scientific-advisory-board-with-internationally-renowned-interventional-oncologist-thierry-de-baere-md-phd/2025-10-13T18:14:32+00:00https://renovorx.com/how-skipping-the-cro-helped-renovorx-get-closer-to-patients/2025-09-24T19:52:31+00:00https://renovorx.com/renovorx-panther-study-progresses-with-first-clinical-procedure/2025-09-26T20:36:46+00:00https://renovorx.com/from-trials-to-hope-a-new-approach-to-treating-pancreatic-cancer/2025-09-27T20:51:15+00:00https://renovorx.com/expanding-solid-tumor-care-shaun-bagai-from-renovorx-in-a-stimulating-conversation-with-pharmashots/2025-09-29T20:57:22+00:00https://renovorx.com/pharmashots-webinar-mastering-a-patient-centric-approach-for-treatment-in-biopharma/2025-08-29T21:03:55+00:00https://renovorx.com/renovorx-updates-pivotal-tiger-pac-trial-of-pancreatic-cancer-treatment/2025-08-20T21:10:08+00:00https://renovorx.com/renovorx-launches-post-marketing-study-to-advance-real-world-use-of-renovocath-device/2025-07-28T21:32:00+00:00https://renovorx.com/sio-2026-annual-scientific-meeting-savannah-ga-february-4-8-2026/2020-02-04T07:00:46+00:00https://renovorx.com/sso-2026-annual-meeting-march-5-7-2026-phoenix-az-february-4-8-2026/2020-03-05T07:00:39+00:00https://renovorx.com/renovorx-strengthens-scientific-advisory-board-sab-with-pancreatic-cancer-expert-timothy-donahue-md/2025-11-07T00:51:16+00:00https://renovorx.com/first-patient-treated-in-renovocath-clinical-trial/2025-11-11T05:53:40+00:00https://renovorx.com/revolutionizing-cancer-treatment-the-future-of-localized-drug-delivery-to-tumors-with-ceo-shaun-bagai/2025-11-26T01:04:41+00:00https://renovorx.com/renovorx-announces-acceptance-of-clinical-data-abstract-at-the-asco-gastrointestinal-cancers-symposium-2026/2026-10-05T20:51:13+00:00https://renovorx.com/renovorx-to-announce-promising-new-clinical-data-using-its-tamp-therapy-platform-in-an-abstract-to-be-presented-at-asco-gi-2026/2026-10-05T20:51:13+00:00https://renovorx.com/renovorx-expands-renovocath-commercial-adoption-to-nine-active-cancer-centers-including-city-of-hope-cancer-center-and-moffitt-cancer-center/2026-10-05T20:51:13+00:00https://renovorx.com/nanoparticles-and-beyond-novel-drug-delivery-strategies-for-cancer/2026-08-17T19:48:57+00:00https://renovorx.com/ntra-arterial-gemcitabine-vs-intravenous-gemcitabine-pharmacokinetic-and-pharmacodynamic-sub-study-of-the-tiger-pac-phase-3-clinical-trial-presented-at-asco-gastrointestinal-cancers-symposium-2026-j/2026-01-21T21:05:22+00:00https://renovorx.com/renovorx-announces-acceptance-of-clinical-data-abstract-at-2026-society-of-interventional-oncology-annual-scientific-meeting/2026-10-05T20:51:13+00:00https://renovorx.com/interview-with-shaun-bagai-revolutionary-cancer-treatment-startup-success-medtech-mentorship/2026-09-08T14:43:37+00:00https://renovorx.com/sir-2026-annual-scientific-meeting-toronto-canada-april-11-15-2026/2020-04-11T07:00:05+00:00https://renovorx.com/2026-asco-annual-meeting-chicago-il-may-29-june-2-2026/2020-05-29T07:00:41+00:00https://renovorx.com/symposium-of-clinical-oncology-miami-beach-fl-september-25-27-2026/2020-09-25T07:00:41+00:00https://renovorx.com/astro-annual-meeting-boston-ma-september-26-30-2026/2020-09-26T07:00:02+00:00https://renovorx.com/renovorx-announces-clinical-data-supporting-the-tamp-therapy-platform-will-be-presented-at-the-sio-2026-annual-scientific-meeting/2026-10-05T20:51:14+00:00https://renovorx.com/renovorx-appoints-experienced-public-company-executive-mark-voll-as-chief-financial-officer/2026-10-05T20:51:14+00:00https://renovorx.com/renovorx-establishes-renovocath-medical-advisory-board/2026-10-06T00:42:11+00:00https://renovorx.com/real-time-intravascular-pressure-measurements-during-double-balloon-catheter-mediated-trans-arterial-micro-perfusion-to-optimize-drug-delivery-in-solid-tumors-presented-at-sio-2026-annual-scientific-m/2026-02-11T01:00:15+00:00https://renovorx.com/renovorx-announces-acceptance-of-clinical-data-abstract-at-2026-society-of-interventional-radiology-annual-scientific-meeting/2026-10-05T20:51:14+00:00https://renovorx.com/renovorx-advancing-renovocath-adoption-at-u-s-cancer-centers-strengthening-clinical-and-commercial-momentum/2026-10-06T00:42:11+00:00https://renovorx.com/delivering-therapy-where-it-matters-presented-at-sio-2026-annual-scientific-meetings-discovery-theater-panel-discussion/2026-03-04T01:59:28+00:00https://renovorx.com/mark-voll-joins-renovorx-as-chief-financial-officer/2026-02-20T02:01:15+00:00https://renovorx.com/why-commercial-discipline-starts-long-before-launch/2026-02-18T02:08:27+00:00https://renovorx.com/renovorx-announces-10-million-at-market-private-placement/2026-10-05T20:51:15+00:00https://renovorx.com/renovorx-announces-closing-of-oversubscribed-10-million-at-market-private-placement/2026-10-05T20:51:15+00:00https://renovorx.com/renovorx-announces-key-phase-iii-milestone-tiger-pac-trial-surpasses-100-randomized-patients-as-study-nears-completion-of-enrollment/2026-10-06T00:42:03+00:00https://renovorx.com/renovorx-reports-full-year-2025-financial-results-and-provides-business-update/2026-10-06T00:42:01+00:00https://renovorx.com/renovorx-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026/2026-10-05T20:51:16+00:00https://renovorx.com/renovorx-secures-first-notice-of-allowance-for-japanese-patent-covering-its-renovocath-device-for-targeted-local-drug-delivery-via-the-vasa-vasorum/2026-10-06T00:42:10+00:00https://renovorx.com/clinical-data-supporting-targeted-chemotherapeutic-delivery-via-renovorxs-tamp-therapy-platform-presented-at-2026-sir-annual-scientific-meeting/2026-10-06T00:42:10+00:00https://renovorx.com/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamp-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting/2026-08-19T16:27:47+00:00https://renovorx.com/renovorx-to-host-first-quarter-2026-financial-results-and-business-highlights-conference-call-on-may-14th-at-430-pm-et/2026-04-30T02:39:47+00:00https://renovorx.com/the-most-innovative-medical-device-companies-of-2026/2026-05-09T03:25:43+00:00https://renovorx.com/what-pet-ct-reveals-after-transarterial-microperfusion-for-pancreatic-cancer-presented-at-sir-2026-annual-scientific-meeting-april-2026/2026-05-09T13:15:54+00:00https://renovorx.com/renovorx-reports-record-first-quarter-2026-increasing-revenue-by-136-quarter-over-quarter/2026-10-06T00:42:01+00:00https://renovorx.com/renovorx-to-present-at-the-alliance-global-partners-virtual-annual-healthcare-company-showcase-on-may-20th/2026-10-05T20:51:17+00:00https://renovorx.com/renovorx-announces-promising-pharmacokinetic-data-using-the-tamp-platform-presented-at-the-2026-asco-annual-meeting/2026-10-06T00:42:03+00:00https://renovorx.com/renovorx-announces-fda-orphan-drug-designation-granted-oxaliplatin-for-the-treatment-of-pancreatic-cancer/2026-10-05T20:51:17+00:00https://renovorx.com/renovorx-ceo-shaun-bagai-to-present-at-the-iaccess-alpha-virtual-best-ideas-summer-investment-conference-2026-on-june-23rd/2026-10-05T20:51:17+00:00https://renovorx.com/renovorx-highlights-peer-reviewed-publication-supporting-intra-arterial-gemcitabine-delivery-via-tamp-in-locally-advanced-pancreatic-cancer/2026-10-06T00:42:07+00:00https://renovorx.com/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-conference-call-on-august-12th-at-430-p-m-et/2026-10-06T00:42:05+00:00https://renovorx.com/renovorx-to-highlight-tamp-platform-at-jonestrading-virtual-key-opinion-leader-webinar-on-the-evolving-pancreatic-cancer-landscape-august-13th/2026-10-06T00:42:10+00:00https://renovorx.com/renovorx-named-tie50-2013-winner/2013-05-20T22:06:25+00:00https://renovorx.com/renovorx-board-names-shaun-r-bagai-ceo/2014-10-27T15:00:22+00:00https://renovorx.com/renovorx-patent-approved/2014-10-28T15:00:16+00:00https://renovorx.com/renovocath-rc120-receives-fda-clearance/2014-10-30T15:00:25+00:00https://renovorx.com/renovorx-announces-first-commercial-clinical-use-of-renovocath-in-sarcoma-patient-treatment-marking-expansion-of-targeted-drug-delivery-device-to-other-solid-tumors/2026-10-06T00:42:08+00:00https://renovorx.com/renovorx-achieves-major-milestone-with-full-enrollment-in-phase-iii-tiger-pac-trial-for-locally-advanced-pancreatic-cancer/2026-10-06T00:42:02+00:00https://renovorx.com/renovorx-reports-record-second-quarter-2026-results-driven-by-accelerating-commercial-adoption-and-61-sequential-quarterly-revenue-growth/2026-10-06T00:41:59+00:00https://renovorx.com/tamp-mediated-gemcitabine-lowers-systemic-exposure-vs-iv-delivery-in-locally-advanced-pancreatic-cancer/2026-09-17T21:22:29+00:00https://renovorx.com/winship-offers-tamp-therapy-platform-for-locally-advanced-pancreatic-cancer/2026-10-06T00:42:15+00:00https://renovorx.com/renovorx-announces-peer-reviewed-publication-highlighting-the-tamp-platforms-potential-to-improve-chemotherapeutic-delivery-for-locally-advanced-pancreatic-cancer/2026-10-06T00:42:14+00:00